|
gptkbp:instanceOf
|
gptkb:vasodilator
gptkb:chemical_compound
gptkb:potassium_channel_opener
gptkb:antihypertensive_agent
|
|
gptkbp:affiliatedWith
|
benzothiadiazine class
|
|
gptkbp:ATCCode
|
C02DA01
|
|
gptkbp:CASNumber
|
364-98-7
|
|
gptkbp:chemicalFormula
|
C8H7ClN2O2S
|
|
gptkbp:contraindication
|
compensated heart failure
functional hypoglycemia
hypersensitivity to diazoxide
|
|
gptkbp:discoveredBy
|
gptkb:Bayer
|
|
gptkbp:discoveredIn
|
1960s
|
|
gptkbp:eliminationHalfLife
|
21-45 hours
|
|
gptkbp:excretion
|
renal
|
|
gptkbp:IUPACName
|
7-chloro-3-methyl-2H-1,2,4-benzothiadiazine 1,1-dioxide
|
|
gptkbp:KEGGID
|
D00318
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:mechanismOfAction
|
opens ATP-sensitive potassium channels
|
|
gptkbp:meltingPoint
|
230-232 °C
|
|
gptkbp:metabolism
|
hepatic
|
|
gptkbp:molecularWeight
|
230.67 g/mol
|
|
gptkbp:pregnancyCategory
|
C
|
|
gptkbp:PubChem_CID
|
gptkb:CHEMBL1427
3016
DB01119
|
|
gptkbp:routeOfAdministration
|
oral
intravenous
|
|
gptkbp:sideEffect
|
hypotension
tachycardia
hyperglycemia
fluid retention
|
|
gptkbp:synonym
|
Hyperstat
Proglycem
|
|
gptkbp:UNII
|
GFO928U08A
|
|
gptkbp:usedFor
|
treatment of hypertensive emergencies
treatment of hypoglycemia
|
|
gptkbp:bfsParent
|
gptkb:insulinoma
|
|
gptkbp:bfsLayer
|
6
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
diazoxide
|